NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today announced that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will deliver a corporate presentation at the BIO 2010 International Convention on Tuesday, May 4 at McCormick Place Convention Center in Chicago.
Dr. Najafi’s presentation will take place at 3:30 p.m. CDT in Presentation Room C, as part of the 2010 BIO Business Forum. His presentation will provide a corporate overview and highlight the clinical progress of the company’s internal programs and its development programs with partners Alcon (NYSE:ACL) and Galderma S.A. Dr. Najafi will also review the positive results from the company’s recently completed exploratory open label Phase 2a trial in the area of Catheter-Associated Urinary Tract Infection.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay’s Aganocide compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a license and research collaboration agreement with Alcon, Inc. for use of NovaBay’s Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize NovaBay’s Aganocide compounds in acne, impetigo and other dermatological indications. For more information visit: www.novabaypharma.com.
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson
NovaBay Pharmaceuticals, Inc.
Director of Corporate Communications